MFN Partners Management, LP - Q2 2019 holdings

$630 Million is the total value of MFN Partners Management, LP's 17 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 26.7% .

 Value Shares↓ Weighting
AGN BuyALLERGAN PLC$150,704,000
+58.3%
900,101
+38.5%
23.92%
+55.8%
FOXA  FOX CORP$86,812,000
-0.2%
2,369,3310.0%13.78%
-1.8%
PCG SellPG&E CORP$64,176,000
-9.9%
2,800,000
-30.0%
10.19%
-11.3%
IRWD  IRONWOOD PHARMACEUTICALS INC$54,039,000
-19.1%
4,939,5410.0%8.58%
-20.4%
XPO BuyXPO LOGISTICS INC$52,835,000
+16.3%
913,935
+8.1%
8.39%
+14.4%
LNG  CHENIERE ENERGY INC$51,338,000
+0.1%
750,0000.0%8.15%
-1.5%
GS  GOLDMAN SACHS GROUP INC$35,562,000
+6.6%
173,8110.0%5.64%
+4.9%
PXD  PIONEER NAT RES CO$30,772,000
+1.0%
200,0000.0%4.88%
-0.6%
FG  FGL HLDGS$25,200,000
+6.7%
3,000,0000.0%4.00%
+5.0%
GTTN BuyGTT COMMUNICATIONS INC$22,000,000
-36.6%
1,250,000
+25.0%
3.49%
-37.6%
CYCN NewCYCLERION THERAPEUTICS INC$17,036,0001,487,874
+100.0%
2.70%
LBTYK NewLIBERTY GLOBAL PLC$16,596,000625,558
+100.0%
2.64%
TAK  TAKEDA PHARMACEUTICAL CO LTDsponsored ads$13,895,000
-13.1%
785,0000.0%2.21%
-14.5%
NAVI SellNAVIENT CORPORATION$3,335,000
-55.7%
244,300
-62.4%
0.53%
-56.4%
ACRS  ACLARIS THERAPEUTICS INC$3,285,000
-63.4%
1,500,0000.0%0.52%
-64.0%
EOLS NewEVOLUS INC$1,754,000120,000
+100.0%
0.28%
RVNC  REVANCE THERAPEUTICS INC$597,000
-17.7%
46,0000.0%0.10%
-18.8%
BMY ExitBRISTOL MYERS SQUIBB COcall$0-1,000,000
-100.0%
-7.70%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-08-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
XPO LOGISTICS INC20Q3 202331.8%
LIBERTY GLOBAL PLC- C18Q3 202318.6%
CYCLERION THERAPEUTICS INC16Q1 20232.7%
HCA HEALTHCARE INC15Q3 202310.9%
CHENIERE ENERGY INC13Q4 202119.2%
OCCIDENTAL PETROLEUM CORP13Q3 202310.5%
PENNYMAC FINL SVCS INC NEW11Q3 202312.2%
ALPHABET INC-CL A9Q2 202312.9%
LITHIA MTRS INC8Q3 202316.0%
META PLATFORMS INC7Q4 202114.1%

View MFN Partners Management, LP's complete holdings history.

Latest significant ownerships (13-D/G)
MFN Partners Management, LP Q2 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Foley Trasimene Acquisition Corp.March 15, 20215,000,0004.8%
Cyclerion Therapeutics, Inc.February 12, 20212,427,6777.2%
Foley Trasimene Acquisition Corp.February 12, 202114,000,00013.5%
Foley Trasimene Acquisition IISold outFebruary 12, 202100.0%
Aclaris Therapeutics, Inc.July 22, 20201,895,6774.5%

View MFN Partners Management, LP's complete significant-ownership history.

Latest filings
TypeFiled
42024-04-26
42024-04-24
42024-04-19
42024-04-17
13F-HR2024-02-13
42024-02-12
42024-02-06
42023-11-24
42023-11-20
42023-11-15

View MFN Partners Management, LP's complete filings history.

Compare quarters

Export MFN Partners Management, LP's holdings